Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 12, 2017
Pharmacy Choice - News - Front Page Healthcare News - December 12, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/12/17 - 2017, Report on Global Veterinary Surgical Instruments Sales Market
The global veterinary surgical instrument market is projected to attain huge revenue by 2022, according to a report available on Radiant Insights, Inc. It is anticipated to exhibit a steady CAGR over the forecast period (from 2012 to 2022). High rate...
12/12/17 - 42 Biggest Movers From Yesterday
Gainers Yield10 Bioscience Inc shares jumped 183.59 percent to close at $5.53 on Monday after the company reported granting of research license to Monsanto for evaluation of 2 novel yield traits in soybean. ARGENX SE/ S ADR shares climbed 78.88 percent to close at $54.47 after the company reported positive topline results from Phase 2 proof-of-conc
12/12/17 - AbbVie Announces Phase 3 Study of VENCLEXTA?/ VENCLYXTO? (venetoclax) in Combination with Rituxan (rituximab) Meets its Primary Endpoint
AbbVie, a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety results from MURANO, an international, multicenter, open-label, randomized Phase 3 study of VENCLEXTA?/ VENCLYXTO? in combination with Rituxan compared with bendamustine in combination with Rituxan in pat
12/12/17 - Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology
CAMBRIDGE- Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced preliminary results from the ongoing Phase 2 trials with luspatercept in patients with lower-risk myelodysplastic syndromes at the 59th Annual Meeting of the American...
12/12/17 - Acer Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
Acer Therapeutics Inc., a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the pricing of its underwritten public offering of 916,667 shares of its common stock at a public offering price of $12.00 per share.
12/12/17 - ADHD Therapeutics Market Healthy Growth Rate by Top Players, Major Types, Revenue and Forecasts Till 2024
ADHD Therapeutics Market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East& Africa. Concordia International Corp., Eli Lilly and Company, Highland Therapeutics Inc., Janssen Global Services LLC, NEOS Therapeutics Inc., Novartis AG, Noven Pharmaceuticals Inc., Pfizer
12/12/17 - ADMA Files Biologics License Application For Its Third Plasma Collection Center [Algeria Press Service]
ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease and the prevention and treatment of certain infectious diseases, announces the filing of a Biologics License Application for its third...
12/12/17 - Agency Information Collection Activities: Submission for Office of Management and Budget Review; Comment Request; Applications for Food and Drug Administration Approval To Market a New Drug
All comments should be identified with the OMB control number 0910-0001. Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Under section 505 of the Fede
12/12/17 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Orphan Products Development; Food and Drug Administration Orphan Drug Designation Request Form and The Common European Medicines Agency/
All comments should be identified with the OMB control number 0910-0167. Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Sections 525 through 528 of t
12/12/17 - Akron Children's Hospital adding pediatric care services, building at Stark hospital property in North Canton [The Akron Beacon Journal]
Dec. 11 Akron Children's Hospital is expanding its services in North Canton and throughout the region. The hospital will offer pediatric primary and specialty care at a new three-story, 38,000- square-foot building to be constructed on Aultman Hospital property as part of a long-term lease. Other locations will include new centers to be built in
12/12/17 - Alembic Pharma gains 1% as associate company gets US FDA approval [Arab News (Saudi Arabia)]
Rhizen Pharmaceuticals SA, an associate company of Alembic Pharmaceuticals, today announced that the US FDA has granted Fast Track Designation for RP6530, the company`s highly selective and orally active dual PI3K delta/ gamma inhibitor, for the treatment of patients with relapsed/ refractory peripheral T-cell lymphoma. In the morning session, Alem
12/12/17 - Alembic Pharma gains on USFDA approval for Darifenacin [India Infoline News Service]
Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application Darifenacin Extended- Release Tablets, 7.5 mg and 15 mg. Alembic Pharmaceuticals, a leading pharmaceutical company, is a market leader in the macrolides segment of anti-infective dr
12/12/17 - Allergan Receives FDA Clearance For the CoolSculpting Treatment To Improve Appearance Of Lax Tissue In The Double Chin
Allergan plc today announced that the CoolSculpting treatment is the first and only non-surgical fat reduction technology to be FDA- cleared for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments. "A 2017 American Society for Dermatologic Surgery survey revealed that 73 percent of patients are both
12/12/17 - Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of adults with hereditary transthyretin-mediated amyloidosis.
12/12/17 - Ambulatory Services Market Size Projected to Grow At 6% CAGR Till 2024 | Hexa Research
Rising government spending on ambulatory care facilities couples with increasing government initiatives to offer team-based primary care are expected to be key factors contributing towards the growth of the "Ambulatory Services Market". The global Ambulatory Services Market is projected to expand at a moderate CAGR of nearly 6% over the forecast pe
12/12/17 - Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs
CINCINNATI and CAMBRIDGE, England, Dec. 12, 2017/ PRNewswire/ Aprecia Pharmaceuticals, LLC, The 3 DP Pharmaceutical Company, and Cycle Pharmaceuticals, Ltd. today announced they have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed technology. The planned products will deliver quality-of-l
12/12/17 - AstraZeneca's CALQUENCE demonstrates activity in relapsed or refractory mantle cell lymphoma trial
AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration accelerated approval of CALQUENCE. CALQUENCE was granted accelerated approval by the US Food
12/12/17 - AstraZeneca's CALQUENCE shows potential in chronic lymphocytic leukemia trials
AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial and updated results from the Phase I/II ACE-CL-001 clinical trial that are evaluating acalabrutinib alone and in combination for the treatment of chronic lymphocytic leukemia in multiple
12/12/17 - AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND Submission
AXIM Biotechnologies, Inc., a world leader in cannabinoid research and development, announced today that it has successfully completed a pre-investigational New Drug Application meeting with the U.S. Food and Drug Administration for a dronabinol-based functional, controlled-release chewing gum product it s developing to help treat patients
12/12/17 - AXON Meets the First Milestone in an nfvPPA Phase 1 Study With AADvac1
AXON has announced the initiation of open recruitment in the currently running Phase 1 study in patients suffering from the non-fluent variant of Primary Progressive Aphasia. In August 2017, AXON launched in cooperation with the German FTLD consortium a Phase I study assessing its active tau vaccine in patients with nfvPPA. Markus Otto, the co-ordi
12/12/17 - BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib Combined with GAZYVA at the 59th American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. and BEIJING- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today presented updated preliminary clinical data from an ongoing Phase 1 b trial of its investigational Bruton's Tyrosine Kinase..
12/12/17 - BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
SAN RAFAEL- BioMarin Pharmaceutical Inc. announced today an update to its previously reported results of an open-label Phase 1/ 2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia A. The updated results will be presented during an oral presentation at the 59th American Society of Hematology Annual.
12/12/17 - BioPharmX Reports Third Quarter 2018 Financial Results
MENLO PARK, Calif.- BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, today announces its financial results for the third quarter ended October 31, 2017. 'We achieved important regulatory and financial milestones during the quarter,' said BioPharmX president Anja Krammer.' The Food and Drug Administration concurred
12/12/17 - BioReference Laboratories Supports ACLA Suit Calling to Rescind PAMA Reimbursement Rate
BioReference Laboratories, Inc., one of the nation's largest, full-service clinical diagnostic laboratories, applauds the American Clinical Laboratory Association' s decision to advocate for Medicare beneficiaries and laboratories alike by filing suit against the Acting Secretary of the U.S. Department of Health and Human Services.
12/12/17 - Botanical and Plant-Derived Drugs - Analysis, Trends & Forecasts to 2022 - Research and Markets
The "Botanical and Plant-Derived Drugs: Global Markets" report has been added to Research and Markets' offering. The Global Market for Botanical and Plant-Derived Drugs will Grow from $29.4 Billion in 2017 to around $39.6 Billion by 2022 with a CAGR of 6.1%.. For the purposes of this report, botanicals are those drugs that are FDA- approved under t
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415